Volanesorsen and triglyceride levels in familial chylomicronemia syndrome
New England Journal of Medicine Aug 13, 2019
Witztum JL, Gaudet D, Freedman SD, et al. - Researchers evaluated the safety and efficacy of volanesorsen in a phase 3, double-blind, randomized, 52-week trial. The study sample consisted of 66 patients with familial chylomicronemia syndrome who were randomized in a 1:1 ratio to receive volanesorsen or placebo. Volanesorsen treatment reduced triglyceride levels to < 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Adverse events commonly encountered included thrombocytopenia and injection-site reactions.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries